Datascope has sold its patient monitoring division to a subsidiary of Mindray Medical International.

The transaction has a pre-tax value to Datascope of approximately $240 million. Datascope received $209 million from Mindray and retained roughly $31 million in patient monitoring accounts receivable. Datascope said it estimates that upon collection of those receivables, the net after-tax proceeds of the transaction will equal roughly $185 million.

Datascope develops, manufactures and markets products for clinical healthcare markets in interventional cardiology, cardiovascular surgery, vascular surgery and critical care.

SOURCE: FDA NEWS